Enzon annouces termination of agreements with Inex
After a careful evaluation, ENZON determined it will not support further development of MARQIBO. In January 2005, the United States Food and Drug Administration (FDA) provided an action letter detailing MARQIBO is "not approvable" under the FDA's accelerated approval regulations for relapsed aggressive non-Hodgkin's lymphoma. The FDA's response also stated additional randomized controlled studies would need to be conducted prior to re-applying for approval. After a strategic analysis of the FDA's recommendation, required investment, development timeframe, and associated development risks, the Company concluded it would be in its best interest to redirect this investment to pursue other opportunities.
ENZON expects to pay INEX $5 million for certain contractual obligations, including development expenses and milestone payments.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.